Literature DB >> 16889722

[Analysis of the factors affecting the recurrence of giant cell tumor of bone].

Qian-chen Guo1, Jing-nan Shen, Jin Wang, Gang Huang, Chang-ye Zou, Song Jin, Jun-qiang Yin, Wei-ming Liao.   

Abstract

OBJECTIVE: To analyze the clinical factors affecting the recurrence of giant cell tumors (GCT) of bone.
METHODS: The complete data of 146 cases with GCT were reviewed. Thirteen clinical factors were analyzed by chi(2) analysis. And the related Campanacci's grade system and Jaffe's grade system was analyzed by Crosstabs analysis. Multipal factors were analyzed by Logistic regression analysis.
RESULTS: Nineteen of 146 cases recurred, and recurrence rate was 13.0%. Recurrence rates of curettage and enblock resection groups were 18.8% and 6.3% respectively. And recurrence rates of curettage with or without of extensive procedure were 12.9% and 38.9%. Five cases had lung metastasis, and two cases presented with malignant transformation. The metastasis rate and the rate of malignant transformation were 3.4% and 1.4% respectively. The two factors of surgery method and burst out of bone-envelope appearance were related with the recurrence. Moreover, Logistic regression revealed that the surgery method significantly affected the recurrence. And Campanacci's grade system and Jaffe's grade system were not related to each other.
CONCLUSIONS: Surgery method is the main factor affected the recurrence of GCT, and Campanacci's grade system or Jaffe's grade system has no prognostic value.

Entities:  

Mesh:

Year:  2006        PMID: 16889722

Source DB:  PubMed          Journal:  Zhonghua Wai Ke Za Zhi        ISSN: 0529-5815


  2 in total

1.  Which treatment is the best for giant cell tumors of the distal radius? A meta-analysis.

Authors:  Yu-Peng Liu; Kang-Hua Li; Bu-Hua Sun
Journal:  Clin Orthop Relat Res       Date:  2012-07-07       Impact factor: 4.176

2.  The prognosis of giant cell tumor of bone and the vital risk factors that affect its postoperative recurrence: a meta-analysis.

Authors:  Xunge Lin; Jiaqi Liu; Meng Xu
Journal:  Transl Cancer Res       Date:  2021-04       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.